Christopher Fladd
University of Toronto
15 Papers
124 Citations
Christopher Fladd is an academic researcher from University of Toronto. The author has contributed to research in topics: Protein tyrosine phosphatase & Phosphatase. The author has an hindex of 10, co-authored 12 publications. Previous affiliations of Christopher Fladd include Medical Research Council.
Chat about Author
Papers
Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast.
Ronish Gupta,Bart Kus,Christopher Fladd,James D. Wasmuth,Raffi Tonikian,Sachdev S. Sidhu,Nevan J. Krogan,John Parkinson,Daniela Rotin +8 more
TL;DR: The development of a novel proteomic in vitro ubiquitination screen using a protein microarray platform that can be utilized for the discovery of substrates for E3 ligases on a global scale is described.
181
Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays
Avinash Persaud,Philipp Alberts,Eva Amsen,Xuejian Xiong,James D. Wasmuth,Zachary Saadon,Christopher Fladd,John Parkinson,Daniela Rotin +8 more
TL;DR: The feasibility of identifying substrates and deciphering substrate specificity of mammalian E3 ligases is demonstrated and Nedd4‐1 knockdown or knockout in cells led to sustained signalling via some of its substrate Tyr kinases (e.g. FGFR), suggesting Nedd 4‐1 suppresses their signalling.
157
N-Cadherin Is an In Vivo Substrate for Protein Tyrosine Phosphatase Sigma (PTPσ) and Participates in PTPσ-Mediated Inhibition of Axon Growth
TL;DR: It is concluded that N-cadherin is a physiological substrate for PTPσ and that N -caderin (and likely β-catenin) participates in P TPσ-mediated inhibition of axon growth.
56
Use of kinase inhibitors to correct ΔF508-CFTR function.
Agata M. Trzcińska-Daneluti,Leo Nguyen,Chong Jiang,Christopher Fladd,David Uehling,Michael Prakesch,Rima Al-awar,Daniela Rotin +7 more
TL;DR: Several kinase inhibitors that can rescue ΔF508-CFTR to various degrees are identified, and suggest that use of compounds or drugs already in the clinic or in clinical trials for other diseases can expedite delivery of treatment for CF patients.
35
Pituitary, pancreatic and gut neuroendocrine defects in protein tyrosine phosphatase-sigma-deficient mice.
TL;DR: Examination of the role of PTPfinal sigma on pituitary, pancreas and enteroendocrine cytodifferentiation, hormone production, and development in mice shows that it plays a major role in differentiation and development of the neuroendocrine system.
33